The trademark ACHAMTA was filed by Bristol-Myers Squibb Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on April 26, 2021, and received one opposition filed on July 26, 2021 by Novartis AG on Likelihood of confusion. the opponent was represented by Nordemann Czychowski & Partner Rechtsanwältinnen und Rechtsanwälte mbB and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued July 26, 2021
The application was filed in English, and English was also language of all opposition proceedings (French was selected as the second language).